NORCROSS,The stock of SpectRx jumped more than 10 percent this morning on news that Abbott Laboratories would pay the medical technology company $1 million as a milestone payment for the commercialization of its continuous glucose monitoring system.

SpectRx has developed means of obtaining glucose readings in people suffering from diabetes without using needs or drawing blood. A sensor is attached to a person’s skin, and the company says prototypes have demonstrated the capability of obtaining readings once a minute.

SpectRX (Nasdaq: SPRX) shares climbed 25 cents to $2.10 a share.